Covalon Technologies（COV）株式概要コバロン・テクノロジーズ社は、米国、カナダ、中東、アジア、中南米、および国際的な感染管理、高度創傷治療、外科処置分野の医療製品の研究、開発、製造、マーケティングに従事している。 詳細COV ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績2/6財務の健全性6/6配当金2/6報酬当社が推定した公正価値より94.4%で取引されている 収益は年間27.11%増加すると予測されています リスク分析意味のある時価総額がありません ( CA$57M )利益率(3.1%)は昨年より低い(13.6%) すべてのリスクチェックを見るCOV Community Fair Values Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN31.0% undervaluedAnalystConsensusTarget•5mo agoInfection Prevention Demand And International Expansion Will Support Stronger Long Term Earnings1502Top Analyst NarrativesCovalon TechnologiesANAnalystConsensusTargetBased on Analyst Price TargetsInfection Prevention Demand And International Expansion Will Support Stronger Long Term EarningsCatalysts About Covalon Technologies Covalon Technologies develops and commercializes infection prevention and advanced wound care products that help clinicians improve patient outcomes in demanding care settings. What are the underlying business or industry changes driving this perspective?View narrativeCA$2.9FV31.0% 割安 内在価値ディスカウント10.12%Revenue growth p.a.Set Fair ValueView15users have viewed this narrative0users have liked this narrative0users have commented on this narrative2users have followed this narrative5 months ago author updated this narrativeView all narrativesCovalon Technologies Ltd. 競合他社Vaxil BioSymbol: TSXV:VXLMarket cap: CA$896.4kBioSyentSymbol: TSXV:RXMarket cap: CA$160.1mNoveris Health SciencesSymbol: CNSX:NVRSMarket cap: CA$115.3mAuxly Cannabis GroupSymbol: TSX:XLYMarket cap: CA$204.1m価格と性能株価の高値、安値、推移の概要Covalon Technologies過去の株価現在の株価CA$2.0052週高値CA$3.1052週安値CA$1.55ベータ-0.0151ヶ月の変化2.56%3ヶ月変化24.22%1年変化-26.20%3年間の変化-6.54%5年間の変化37.93%IPOからの変化-33.33%最新ニュースお知らせ • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026Major Estimate Revision • Mar 04Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CA$38.4m to CA$36.4m. EPS estimate also fell from CA$0.12 per share to CA$0.07 per share. Net income forecast to grow 172% next year vs 16% decline forecast for Biotechs industry in Canada. Consensus price target of CA$2.90 unchanged from last update. Share price rose 4.9% to CA$1.91 over the past week.Reported Earnings • Feb 26First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$6.89m (down 16% from 1Q 2025). Net income: CA$125.4k (down 90% from 1Q 2025). Profit margin: 1.8% (down from 15% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 60% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Feb 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Samantha Nutt was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.最新情報をもっと見るRecent updatesお知らせ • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026Major Estimate Revision • Mar 04Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CA$38.4m to CA$36.4m. EPS estimate also fell from CA$0.12 per share to CA$0.07 per share. Net income forecast to grow 172% next year vs 16% decline forecast for Biotechs industry in Canada. Consensus price target of CA$2.90 unchanged from last update. Share price rose 4.9% to CA$1.91 over the past week.Reported Earnings • Feb 26First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$6.89m (down 16% from 1Q 2025). Net income: CA$125.4k (down 90% from 1Q 2025). Profit margin: 1.8% (down from 15% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 60% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Feb 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Samantha Nutt was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.86, the stock trades at a forward P/E ratio of 16x. Average trailing P/E is 22x in the Biotechs industry in North America. Total loss to shareholders of 19% over the past three years.Reported Earnings • Dec 11Full year 2025 earnings released: EPS: CA$0.08 (vs CA$0.11 in FY 2024)Full year 2025 results: EPS: CA$0.08 (down from CA$0.11 in FY 2024). Revenue: CA$32.8m (up 5.3% from FY 2024). Net income: CA$2.06m (down 23% from FY 2024). Profit margin: 6.3% (down from 8.6% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 73% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).お知らせ • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.お知らせ • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.Reported Earnings • Aug 22Third quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.059 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.002 (down from CA$0.059 in 3Q 2024). Revenue: CA$8.37m (down 9.2% from 3Q 2024). Net income: CA$64.6k (down 96% from 3Q 2024). Profit margin: 0.8% (down from 16% in 3Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 68% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$2.88, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 7.5% over the past three years.分析記事 • Aug 20Covalon Technologies Ltd.'s (CVE:COV) Popularity With Investors Is Under Threat From OverpricingTSXV:COV 1 Year Share Price vs Fair Value Explore Covalon Technologies's Fair Values from the Community and select...お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025Reported Earnings • May 29Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.059 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (down from CA$0.059 in 2Q 2024). Revenue: CA$7.59m (down 9.8% from 2Q 2024). Net income: CA$429.1k (down 71% from 2Q 2024). Profit margin: 5.7% (down from 17% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 62% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.お知らせ • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$2.60, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 22x in the Biotechs industry in North America. Total returns to shareholders of 18% over the past three years.分析記事 • Feb 26Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S RatioIt's not a stretch to say that Covalon Technologies Ltd.'s ( CVE:COV ) price-to-sales (or "P/S") ratio of 2.1x seems...Reported Earnings • Feb 21First quarter 2025 earnings released: EPS: CA$0.04 (vs CA$0.035 loss in 1Q 2024)First quarter 2025 results: EPS: CA$0.04 (up from CA$0.035 loss in 1Q 2024). Revenue: CA$8.17m (up 75% from 1Q 2024). Net income: CA$1.21m (up CA$2.06m from 1Q 2024). Profit margin: 15% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 64% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025Reported Earnings • Jan 07Full year 2024 earnings released: EPS: CA$0.11 (vs CA$0.18 loss in FY 2023)Full year 2024 results: EPS: CA$0.11 (up from CA$0.18 loss in FY 2023). Revenue: CA$31.2m (up 17% from FY 2023). Net income: CA$2.67m (up CA$7.13m from FY 2023). Profit margin: 8.6% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 53% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.お知らせ • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025分析記事 • Nov 17Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 29% gain in the last month...New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Market cap is less than US$100m (CA$84.9m market cap, or US$62.6m).Reported Earnings • Aug 22Third quarter 2024 earnings released: EPS: CA$0.06 (vs CA$0.02 loss in 3Q 2023)Third quarter 2024 results: EPS: CA$0.06 (up from CA$0.02 loss in 3Q 2023). Revenue: CA$9.22m (up 47% from 3Q 2023). Net income: CA$1.45m (up CA$1.95m from 3Q 2023). Profit margin: 16% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.分析記事 • Aug 18Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Covalon Technologies Ltd. ( CVE:COV ) shares have been powering on, with a gain of 25...お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024分析記事 • Aug 10We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Jun 16Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is LackingCovalon Technologies Ltd. ( CVE:COV ) shareholders would be excited to see that the share price has had a great month...Reported Earnings • May 30Second quarter 2024 earnings released: EPS: CA$0.06 (vs CA$0.028 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.06 (up from CA$0.028 loss in 2Q 2023). Revenue: CA$8.41m (up 16% from 2Q 2023). Net income: CA$1.46m (up CA$2.16m from 2Q 2023). Profit margin: 17% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024分析記事 • May 01Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Feb 29First quarter 2024 earnings released: CA$0.03 loss per share (vs CA$0.015 loss in 1Q 2023)First quarter 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.015 loss in 1Q 2023). Revenue: CA$4.66m (down 25% from 1Q 2023). Net loss: CA$851.5k (loss widened 124% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.分析記事 • Feb 17Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 25% gain in the last month...Reported Earnings • Jan 28Full year 2023 earnings released: CA$0.18 loss per share (vs CA$0.36 loss in FY 2022)Full year 2023 results: CA$0.18 loss per share (improved from CA$0.36 loss in FY 2022). Revenue: CA$26.6m (up 47% from FY 2022). Net loss: CA$4.46m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.分析記事 • Dec 22Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share PriceWith a price-to-sales (or "P/S") ratio of 1.2x Covalon Technologies Ltd. ( CVE:COV ) may be sending bullish signals at...お知らせ • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.お知らせ • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.お知らせ • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.お知らせ • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.分析記事 • Sep 02We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Aug 17Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.062 loss in 3Q 2022)Third quarter 2023 results: CA$0.02 loss per share (improved from CA$0.062 loss in 3Q 2022). Revenue: CA$6.27m (up 39% from 3Q 2022). Net loss: CA$501.8k (loss narrowed 69% from 3Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.お知らせ • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Amir Boloor was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Amir Boloor was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • May 27Second quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.095 loss in 2Q 2022)Second quarter 2023 results: CA$0.03 loss per share (improved from CA$0.095 loss in 2Q 2022). Revenue: CA$7.24m (up 120% from 2Q 2022). Net loss: CA$698.1k (loss narrowed 72% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.分析記事 • May 26We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023Reported Earnings • Feb 24First quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.043 loss in 1Q 2022)First quarter 2023 results: CA$0.02 loss per share (improved from CA$0.043 loss in 1Q 2022). Revenue: CA$6.19m (up 25% from 1Q 2022). Net loss: CA$380.8k (loss narrowed 66% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023Reported Earnings • Jan 26Full year 2022 earnings released: CA$0.36 loss per share (vs CA$0.016 profit in FY 2021)Full year 2022 results: CA$0.36 loss per share (down from CA$0.016 profit in FY 2021). Revenue: CA$18.1m (down 7.2% from FY 2021). Net loss: CA$9.25m (down CA$9.67m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023お知らせ • Dec 22Covalon Technologies Ltd., Annual General Meeting, Mar 08, 2023Covalon Technologies Ltd., Annual General Meeting, Mar 08, 2023.お知らせ • Nov 02Covalon Technologies Ltd. Announces Its Newest Advanced Wound Care Product, ColActive Plus PowderCovalon Technologies Ltd. announced that its newest advanced wound care product, ColActive Plus Powder, was showcased in a case study presentation at the Symposium on Advanced Wound Care (SAWC), from October 13 to 16, 2022 in Las Vegas. The study, conducted by Dr. Alton Johnson Jr., DPM, FACPM, DABPM, CWSP, at University of Michigan School of Medicine, demonstrates the efficacy of ColActive Plus Powder in treating chronic non-healing wounds. Chronic, hard-to-heal wounds fail to advance through the phases of healing in an orderly and timely manner, often becoming stalled in the inflammatory phase. Imbalances in important cellular mediators for healing perpetuate the cycle of chronicity, which can lead to severe complications such as infection or amputation, which have grave consequences on overall quality of life. ColActive Plus Collagen Powder was uniquely designed to optimize the wound environment while supporting native collagen and connective tissue growth to help clinicians break the cycle of chronicity. Case Study Summary · An 83-year-old patient with peripheral arterial disease underwent metatarsal toe amputation which resulted in non-healing wounds. · The post-amputation surgical wounds failed to heal over several months with use of a competitive collagen/Oxidized Regenerated Cellulose product. · Treatment with weekly pulse lavage and ColActive Plus Powder resulted in the chronic post-amputation wounds being closed within 28 days, remaining healed to date. · Dr. Alton Johnson Jr. concluded that the use of the novel powder preparation of the ColActive formulation, in combination with pulse lavage, initiated and progressed the healing of the patient's chronic wounds rapidly, in addition to being simple to use as part of the existing treatment plan.Covalon's advanced wound care solutions include the following: ColActive® Plus Powder - Collagen wound filler that supports native collagen and connective tissue growth within the wound bed, while also stimulating cellular processes essential for wound healing. Allows for optimal moisture balance. Excellent solution for wounds of irregular shape or wounds in challenging locations ColActive® Plus Powder Ag - Collagen wound filler with antimicrobial ionic silver to prevent bacterial colonization within the product, thus minimizing the risk of infection.お知らせ • Sep 27Covalon Technologies Ltd. to Showcase Infection Prevention Solutions at the Association for Vascular Access Annual Scientific MeetingCovalon Technologies Ltd. announced that it will be co-sponsoring the Association for Vascular Access (AVA) Annual Scientific Meeting and hosting an exhibit from September 30 to October 2, 2022 at the Minneapolis Convention Center, Minneapolis, Minnesota. Visit at booth 607 to learn about advanced infection prevention solutions that reduce the burden on patients, practitioners, and caregivers. Covalon's vascular access infection prevention solutions work to reduce central line-associated bloodstream infections (CLABSIs) while ensuring patient comfort and include: VALGuard - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear- an antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin's barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. VALGuard is the only FDA listed product specifically designed to help prevent vascular line to line contamination, with a safety release mechanism to allow instant access to the line in emergency situations. Vascular access line guards are being recognized as a must-have medical device by major hospitals as 71% of catheter-related infections have been linked to a catheter hub contamination. Patent-pending, VALGuard was developed specifically to help prevent these infections. IV Clear is the world's only clear dual-antimicrobial IV dressing with soft silicone adhesive technology that is designed to protect patients' skin – even after multiple dressing changes. Studies have shown the high efficacy of the product in preventing infections. What may not be as obvious, however, is that the product has been specifically designed with human experience in mind – patients, clinicians, and caregivers. Covalon's patented technology allows for significantly easier application, monitoring and removal, which is imperative for patients with vulnerable skin, such as pediatric ones.お知らせ • Sep 14Covalon Technologies Ltd. to Introduce New Infection Prevention Products at the Annual Association of Pediatric Hematology/Oncology Nurses ConferenceCovalon Technologies Ltd. (the ‘Company’ or ‘Covalon’) to announce its participation in the 46th Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference & Exhibit at the Palm Beach County Convention Center in West Palm Beach, Florida on September 15 17, 2022. Visit Covalon at booth 307 to learn how their infection prevention and advanced wound care products are making a difference in the lives of their youngest patients. With more than 25 leading children's hospitals currently using or evaluating Covalon's VALGuard product, the world's only FDA-approved vascular access line guard, the need to find a solution to help protect line-to-line connections to reduce central line associated bloodstream infections (‘CLABSIs’) has never been greater. Bloodstream infections are up 65% in intensive care units, and there is an urgent need to adopt new compassionate care technologies in the fight to protect patients. The Conference provides premier educational content, networking, and social events for nurses specializing in pediatric hematology/oncology. Covalon will be hosting an exhibit throughout the conference dates. Visit them at booth 307 to learn how their infection prevention and advanced wound care products are making a difference in the lives of their youngest patients. Covalon's patented products include: VALGuard® - an FDA-approved, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. SurgiClear® - a transparent, breathable, fluid impermeable barrier that isolates the wound site from external contamination while providing dual antimicrobial protection throughout the entire surface of the dressing. It uses a low but effective concentration of chlorhexidine and silver embedded into an atraumatic silicone adhesive that covers the entire transparent surface area to allow for easy and consistent monitoring of wound sites. IV Clear® - a vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin's barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.Reported Earnings • Aug 29Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.041 profit in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (down from CA$0.041 profit in 3Q 2021). Revenue: CA$4.53m (down 49% from 3Q 2021). Net loss: CA$1.61m (down 252% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 25Covalon Technologies Ltd. to Report Q3, 2022 Results on Aug 29, 2022Covalon Technologies Ltd. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 29, 2022Reported Earnings • Jun 01Second quarter 2022 earnings released: CA$0.095 loss per share (vs CA$0.011 loss in 2Q 2021)Second quarter 2022 results: CA$0.095 loss per share (down from CA$0.011 loss in 2Q 2021). Revenue: CA$3.29m (down 24% from 2Q 2021). Net loss: CA$2.46m (loss widened CA$2.17m from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • May 27Covalon Technologies Ltd. to Report Q2, 2022 Results on May 30, 2022Covalon Technologies Ltd. announced that they will report Q2, 2022 results Pre-Market on May 30, 2022お知らせ • May 20Covalon Technologies Ltd. Appoints Mark Doolittle as Senior Vice President, Commercial SalesCovalon Technologies Ltd. announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales. Mr. Doolittle brings over 20 years of medical and B2B sales and marketing experience to Covalon. He has substantial leadership experience managing high-performing teams and managing partnerships both domestically and internationally. Prior to joining Covalon, Mr. Doolittle spent the last 12 years at US-based Cantel Medical, the global leader in infection prevention in GI Endoscopy. In his most recent role, he served as the Vice President of US Commercial.お知らせ • Apr 27Covalon Technologies Ltd. Appoints Ron Hebert as Senior Vice President of MarketingCovalon Technologies Ltd. announced that Ron Hebert has joined the Company as Senior Vice President of Marketing. Mr. Hebert brings nearly 30 years of healthcare sales, marketing, and hospital experience to Covalon. Prior to joining the Company, he served as Vice President of Marketing and Communications at VIVEX Biologics. He also served as Vice President and Head of Growth Marketing and Sales Operations at MEDNAX.お知らせ • Feb 17Covalon Technologies Ltd. to Report Q1, 2022 Results on Mar 01, 2022Covalon Technologies Ltd. announced that they will report Q1, 2022 results Pre-Market on Mar 01, 2022Reported Earnings • Dec 15Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CA$0.016 (up from CA$0.27 loss in FY 2020). Revenue: CA$19.6m (down 24% from FY 2020). Net income: CA$419.0k (up CA$7.37m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 3.5%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.Executive Departure • Oct 03Independent Director Myrna Francis has left the companyOn the 24th of September, Myrna Francis' tenure as Independent Director ended after 2.7 years in the role. We don't have any record of a personal shareholding under Myrna's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 5.92 years.Executive Departure • Sep 29Independent Director Myrna Francis has left the companyOn the 24th of September, Myrna Francis' tenure as Independent Director ended after 2.7 years in the role. We don't have any record of a personal shareholding under Myrna's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 5.83 years.Recent Insider Transactions • Sep 15Independent Chairman of the Board recently bought CA$103k worth of stockOn the 8th of September, Amir Boloor bought around 45k shares on-market at roughly CA$2.28 per share. This was the largest purchase by an insider in the last 3 months. Amir has been a buyer over the last 12 months, purchasing a net total of CA$184k worth in shares.Reported Earnings • Sep 01Third quarter 2021 earnings released: EPS CA$0.041 (vs CA$0.012 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$8.82m (up 32% from 3Q 2020). Net income: CA$1.06m (up 237% from 3Q 2020). Profit margin: 12% (up from 4.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year whereas the company’s share price has fallen by 39% per year.お知らせ • Jun 02Covalon Technologies Undertakes A Strategic Review ProcessAs previously announced, in response to expressions of interest made by medical industry and private equity organizations, Board of Directors of Covalon Technologies Ltd. (TSXV:COV) formed a Special Committee and hired advisors to assist in undertaking a Strategic Review process, to ensure that available strategic alternatives to enhance value for our shareholders are being evaluated. Amir Boloor, Chair of Covalon's Board of Directors and Chair of the Special Committee, said, “I am extremely pleased with the progress made by the Special Committee to date. Over the past several months, we have been carefully evaluating a number of expressions of interest and assessing the impact of these potential strategic alternatives on the overall value, future profitability and the growth prospects of Covalon. Each strategic alternative is being evaluated and assessed as to its impact following any strategic transactions involving one or more of our patented intellectual properties, technology platforms, commercialized medical product portfolio and global sales channels. This process has clearly validated that Covalon owns a number of valuable medical technologies that are of interest to the medical industry”.Reported Earnings • Jun 02Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$6.74m (up 28% from 2Q 2020). Net income: CA$421.7k (up CA$4.33m from 2Q 2020). Profit margin: 6.3% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.分析記事 • Apr 29Is Covalon Technologies (CVE:COV) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 03First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.045 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: CA$5.99m (down 25% from 1Q 2020). Net loss: CA$372.3k (loss narrowed 68% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 82% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Feb 27Covalon Technologies Ltd. to Report Q1, 2021 Results on Mar 01, 2021Covalon Technologies Ltd. announced that they will report Q1, 2021 results Pre-Market on Mar 01, 2021Is New 90 Day High Low • Feb 20New 90-day high: CA$1.75The company is up 39% from its price of CA$1.26 on 20 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.Reported Earnings • Jan 30Full year 2020 earnings released: CA$0.27 loss per share (vs CA$0.41 loss in FY 2019)The company reported a mediocre full year result with weaker revenues, although its control over expenses remained stable and losses reduced. Full year 2020 results: Revenue: CA$25.8m (down 24% from FY 2019). Net loss: CA$6.95m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 98% per year but the company’s share price has only fallen by 37% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Jan 27New 90-day high: CA$1.36The company is up 35% from its price of CA$1.01 on 28 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.分析記事 • Dec 29Covalon Technologies (CVE:COV) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Nov 14Covalon Technologies Ltd. Appoints Amir Boloor as Chair of the Company's Board of DirectorsCovalon Technologies Ltd. announced the appointment of Amir Boloor, President of Caspian Equity Partners Inc., as Chair of the Company's Board of Directors. Mr. Boloor, an independent director of the Company, is also Chair of the Company's recently announced Special Committee, appointed to explore and evaluate a range of strategic alternatives available to the Company in order to enhance shareholder value.お知らせ • Aug 22Covalon Technologies Ltd. to Report Q3, 2020 Results on Aug 24, 2020Covalon Technologies Ltd. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Aug 24, 2020株主還元COVCA BiotechsCA 市場7D2.6%3.1%-0.07%1Y-26.2%15.7%33.7%株主還元を見る業界別リターン: COV過去 1 年間で15.7 % の収益を上げたCanadian Biotechs業界を下回りました。リターン対市場: COVは、過去 1 年間で33.7 % のリターンを上げたCanadian市場を下回りました。価格変動Is COV's price volatile compared to industry and market?COV volatilityCOV Average Weekly Movement6.4%Biotechs Industry Average Movement11.3%Market Average Movement10.3%10% most volatile stocks in CA Market18.1%10% least volatile stocks in CA Market3.9%安定した株価: COV 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: COVの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aBrent Ashtoncovalon.comコバロン・テクノロジーズ社は、米国、カナダ、中東、アジア、中南米、および国際的な感染管理、高度創傷治療、外科処置分野の医療製品の研究、開発、製造、マーケティングに従事している。同社のプラットフォーム技術には、糖尿病性潰瘍、褥瘡、静脈性潰瘍、ドナーや移植部位、二次的意図で治癒する外傷、剥離した手術創、第1度・第2度の熱傷などの慢性創傷や感染創傷の治療に使用されるコラーゲンマトリックスプラットフォームや、抗菌シリコーンに接触する細菌や酵母を殺菌するように設計された手術前・手術後、バスキュラーアクセス製品ファミリーに使用される抗菌シリコーン接着剤プラットフォームがある。また、光重合を利用して、新しいポリマー鎖が既存の医療機器の表面から開始され、増殖する活性移植部位を作成するプロセスである医療用コーティングプラットフォームも提供している。さらに、創傷ケア用ドレッシング材、外科・周術期用製品、感染管理製品も提供している。ColActive PLUS、CovaClear、CovaView、CovaWound、IV Clear、SurgiClear、VALGuardのブランド名で製品を提供している。同社は、病院、創傷治療センター、熱傷センター、延長/代替医療施設、急性期医療施設、在宅医療機関、医院などにサービスを提供している。コバロン・テクノロジーズ社は2004年に法人化され、カナダのミシサガに本社を置いている。もっと見るCovalon Technologies Ltd. 基礎のまとめCovalon Technologies の収益と売上を時価総額と比較するとどうか。COV 基礎統計学時価総額CA$57.45m収益（TTM）CA$977.42k売上高(TTM)CA$31.54m56.5xPER（株価収益率1.8xP/SレシオCOV は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計COV 損益計算書（TTM）収益CA$31.54m売上原価CA$15.05m売上総利益CA$16.49mその他の費用CA$15.51m収益CA$977.42k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.035グロス・マージン52.27%純利益率3.10%有利子負債／自己資本比率0%COV の長期的なパフォーマンスは？過去の実績と比較を見る配当金7.5%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 12:51終値2026/05/21 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Covalon Technologies Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Andre UddinResearch Capital Corporation
お知らせ • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026
Major Estimate Revision • Mar 04Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CA$38.4m to CA$36.4m. EPS estimate also fell from CA$0.12 per share to CA$0.07 per share. Net income forecast to grow 172% next year vs 16% decline forecast for Biotechs industry in Canada. Consensus price target of CA$2.90 unchanged from last update. Share price rose 4.9% to CA$1.91 over the past week.
Reported Earnings • Feb 26First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$6.89m (down 16% from 1Q 2025). Net income: CA$125.4k (down 90% from 1Q 2025). Profit margin: 1.8% (down from 15% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 60% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Feb 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Samantha Nutt was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026
お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.
お知らせ • May 15Covalon Technologies Ltd. to Report Q2, 2026 Results on May 21, 2026Covalon Technologies Ltd. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on May 21, 2026
Major Estimate Revision • Mar 04Consensus EPS estimates fall by 42%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CA$38.4m to CA$36.4m. EPS estimate also fell from CA$0.12 per share to CA$0.07 per share. Net income forecast to grow 172% next year vs 16% decline forecast for Biotechs industry in Canada. Consensus price target of CA$2.90 unchanged from last update. Share price rose 4.9% to CA$1.91 over the past week.
Reported Earnings • Feb 26First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$6.89m (down 16% from 1Q 2025). Net income: CA$125.4k (down 90% from 1Q 2025). Profit margin: 1.8% (down from 15% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 60% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Feb 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Samantha Nutt was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 19Covalon Technologies Ltd. to Report Q1, 2026 Results on Feb 25, 2026Covalon Technologies Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 25, 2026
お知らせ • Jan 14Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026Covalon Technologies Ltd., Annual General Meeting, Mar 25, 2026.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.86, the stock trades at a forward P/E ratio of 16x. Average trailing P/E is 22x in the Biotechs industry in North America. Total loss to shareholders of 19% over the past three years.
Reported Earnings • Dec 11Full year 2025 earnings released: EPS: CA$0.08 (vs CA$0.11 in FY 2024)Full year 2025 results: EPS: CA$0.08 (down from CA$0.11 in FY 2024). Revenue: CA$32.8m (up 5.3% from FY 2024). Net income: CA$2.06m (down 23% from FY 2024). Profit margin: 6.3% (down from 8.6% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 73% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Dec 04Covalon Technologies Ltd. to Report Q4, 2025 Results on Dec 11, 2025Covalon Technologies Ltd. announced that they will report Q4, 2025 results Pre-Market on Dec 11, 2025
お知らせ • Oct 21Covalon Technologies Ltd. Declares First Ever Special Cash Dividend, Payable on November 18, 2025Covalon Technologies Ltd. announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in the aggregate amount of CAD 4,112,711.55, being CAD 0.15 per common share of the Company to be paid on November 18, 2025 to shareholders of record at the close of business on November 4, 2025 (the “Record Date”).
お知らせ • Sep 26Covalon Technologies Ltd. Presents Evidence-Backed Innovations Making A Difference for Critically Ill Children At AphonCovalon Technologies Ltd. presented evidence-backed innovations making a difference for critically ill Children At Aphon. The company announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference, September 25-27, 2025 in Providence, Rhode Island. The annual conference, attended by more than 800 nurse leaders from across the United States and around the world, is recognized as the premier educational experience for pediatric hematology/oncology nurses, bringing together clinicians and industry experts to advance knowledge, share research, and improve patient outcomes. Last week, the Journal of the Association for Vascular Access (JAVA) published peer-reviewed data from the Children's Hospital at Montefiore describing how the hospital's experience with VALGuard®? Line Guard was associated with positive outcomes, including a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024, and a sustained period of zero CLABSI's (Central Line Associated Blood Stream Infections) in the Pediatric Critical Care Unit. The publication provides peer-reviewed evidence on VALGuard®? and highlight its role in protecting vulnerable pediatric patients. In addition, new economic findings from a U.S. hospital study demonstrated that CovaClear®? silicone dressing, used as a cover for primary dressings, greatly helped reduce unplanned dressing changes caused by soiling, leaks, or contamination. Avoiding unplanned dressing changes translates into measurable cost savings for hospitals and reduced workload for nurses, while preserving skin integrity for patients who already face intensive therapies. These findings underscore the dual impact of Covalon's portfolio which is designed to improve patient outcomes while creating measurable efficiencies for hospitals seeking to optimize both quality of care and economic performance. At APHON, Covalon will showcase the breadth of its vascular access portfolio, including: VALGuard®? Line Guard - A transparent, single-use barrier designed to cover and protect IV line connections and catheter hubs from external contaminants, including body fluids and secretions that can lead to infection. VALGuard®? incorporates a unique quick-release pull strip that enables fast access to the line for clinicians. CovaClear®? Dressings - A family of versatile gentle-to-skin silicone dressings that can be used as a primary IV securement dressing or as a protective cover over existing primary dressings. By helping reduce unplanned primary IV dressing changes caused by soiled, fluid leaks, or external contamination, CovaClear®? helps customers save money on wasted supplies, reduce nursing workload, and supports efforts to preserve patient skin integrity. IV Clear®? Dressings - Afamily of transparent IV securement dressings that combine gentle-to-skin silicone adhesive technology with edge-to-edge coverage of chlorhexidine and silver for antimicrobial protection. IV Clear®? provides complete transparency to the insertion site, supporting routine assessment and better line management. The company's solutions are designed not only to support better outcomes for patients but also to provide hospitals with measurable savings and long-term value.
お知らせ • Sep 24Covalon Technologies Ltd. Announces Board ChangesCovalon Technologies Ltd. announced that Mr. Abe Schwartz has been elected Chair of the Board of the Company. Mr. Schwartz succeeds Mr. Amir Boloor, who has decided to step down as a director and Executive Chair of Covalon with effect September 23, 2025. Mr. Schwartz, a member of the Covalon Board since 2008, has previously served as Covalon Board Chair from 2012 until 2020. He has been a successful Healthcare and I.T. industry entrepreneur, CEO and investor over the past 50 years and is Covalon’s largest shareholder.
Reported Earnings • Aug 22Third quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.059 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.002 (down from CA$0.059 in 3Q 2024). Revenue: CA$8.37m (down 9.2% from 3Q 2024). Net income: CA$64.6k (down 96% from 3Q 2024). Profit margin: 0.8% (down from 16% in 3Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 68% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$2.88, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 7.5% over the past three years.
分析記事 • Aug 20Covalon Technologies Ltd.'s (CVE:COV) Popularity With Investors Is Under Threat From OverpricingTSXV:COV 1 Year Share Price vs Fair Value Explore Covalon Technologies's Fair Values from the Community and select...
お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2025 Results on Aug 21, 2025Covalon Technologies Ltd. announced that they will report Q3, 2025 results Pre-Market on Aug 21, 2025
Reported Earnings • May 29Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.059 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (down from CA$0.059 in 2Q 2024). Revenue: CA$7.59m (down 9.8% from 2Q 2024). Net income: CA$429.1k (down 71% from 2Q 2024). Profit margin: 5.7% (down from 17% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 62% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • May 27Covalon Technologies Ltd. Announces New Clinical Research Evaluating Vascular Access Line GuardCovalon Technologies Ltd. announced that exciting results from a clinical study evaluating the use of its VALGuard Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall - September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.
お知らせ • May 21Covalon Technologies Ltd. to Report Q2, 2025 Results on May 28, 2025Covalon Technologies Ltd. announced that they will report Q2, 2025 results Pre-Market on May 28, 2025
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$2.60, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 22x in the Biotechs industry in North America. Total returns to shareholders of 18% over the past three years.
分析記事 • Feb 26Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S RatioIt's not a stretch to say that Covalon Technologies Ltd.'s ( CVE:COV ) price-to-sales (or "P/S") ratio of 2.1x seems...
Reported Earnings • Feb 21First quarter 2025 earnings released: EPS: CA$0.04 (vs CA$0.035 loss in 1Q 2024)First quarter 2025 results: EPS: CA$0.04 (up from CA$0.035 loss in 1Q 2024). Revenue: CA$8.17m (up 75% from 1Q 2024). Net income: CA$1.21m (up CA$2.06m from 1Q 2024). Profit margin: 15% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 64% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 14Covalon Technologies Ltd. to Report Q1, 2025 Results on Feb 21, 2025Covalon Technologies Ltd. announced that they will report Q1, 2025 results Pre-Market on Feb 21, 2025
Reported Earnings • Jan 07Full year 2024 earnings released: EPS: CA$0.11 (vs CA$0.18 loss in FY 2023)Full year 2024 results: EPS: CA$0.11 (up from CA$0.18 loss in FY 2023). Revenue: CA$31.2m (up 17% from FY 2023). Net income: CA$2.67m (up CA$7.13m from FY 2023). Profit margin: 8.6% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 53% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 06Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025Covalon Technologies Ltd., Annual General Meeting, Mar 19, 2025.
お知らせ • Dec 19Covalon Technologies Ltd. to Report Q4, 2024 Results on Jan 07, 2025Covalon Technologies Ltd. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Jan 07, 2025
分析記事 • Nov 17Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 29% gain in the last month...
New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Market cap is less than US$100m (CA$84.9m market cap, or US$62.6m).
Reported Earnings • Aug 22Third quarter 2024 earnings released: EPS: CA$0.06 (vs CA$0.02 loss in 3Q 2023)Third quarter 2024 results: EPS: CA$0.06 (up from CA$0.02 loss in 3Q 2023). Revenue: CA$9.22m (up 47% from 3Q 2023). Net income: CA$1.45m (up CA$1.95m from 3Q 2023). Profit margin: 16% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
分析記事 • Aug 18Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Covalon Technologies Ltd. ( CVE:COV ) shares have been powering on, with a gain of 25...
お知らせ • Aug 14Covalon Technologies Ltd. to Report Q3, 2024 Results on Aug 21, 2024Covalon Technologies Ltd. announced that they will report Q3, 2024 results Pre-Market on Aug 21, 2024
分析記事 • Aug 10We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Jun 16Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is LackingCovalon Technologies Ltd. ( CVE:COV ) shareholders would be excited to see that the share price has had a great month...
Reported Earnings • May 30Second quarter 2024 earnings released: EPS: CA$0.06 (vs CA$0.028 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.06 (up from CA$0.028 loss in 2Q 2023). Revenue: CA$8.41m (up 16% from 2Q 2023). Net income: CA$1.46m (up CA$2.16m from 2Q 2023). Profit margin: 17% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2024 Results on May 29, 2024Covalon Technologies Ltd. announced that they will report Q2, 2024 results Pre-Market on May 29, 2024
分析記事 • May 01Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Feb 29First quarter 2024 earnings released: CA$0.03 loss per share (vs CA$0.015 loss in 1Q 2023)First quarter 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.015 loss in 1Q 2023). Revenue: CA$4.66m (down 25% from 1Q 2023). Net loss: CA$851.5k (loss widened 124% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
分析記事 • Feb 17Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 25% gain in the last month...
Reported Earnings • Jan 28Full year 2023 earnings released: CA$0.18 loss per share (vs CA$0.36 loss in FY 2022)Full year 2023 results: CA$0.18 loss per share (improved from CA$0.36 loss in FY 2022). Revenue: CA$26.6m (up 47% from FY 2022). Net loss: CA$4.46m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Jan 26+ 1 more updateCovalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - OperationsCovalon Technologies Ltd. announced that Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.
分析記事 • Dec 22Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share PriceWith a price-to-sales (or "P/S") ratio of 1.2x Covalon Technologies Ltd. ( CVE:COV ) may be sending bullish signals at...
お知らせ • Dec 21Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024Covalon Technologies Ltd., Annual General Meeting, Mar 06, 2024.
お知らせ • Oct 12Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in ChicagoCovalon Technologies Ltd. announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from October 12 to October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence. Covalon's patented infection prevention and wound care products include: VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.
お知らせ • Sep 28Covalon Technologies Ltd. Announces Chief Executive Officer ChangesCovalon Technologies Ltd. appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer, effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO. Mr. Boloor succeeds Brian Pedlar, who will remain on Covalon’s Board of Directors.
お知らせ • Sep 27Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent DirectorCovalon Technologies Ltd. appointed Joseph Cordiano to serve as lead independent director.
分析記事 • Sep 02We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Aug 17Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.062 loss in 3Q 2022)Third quarter 2023 results: CA$0.02 loss per share (improved from CA$0.062 loss in 3Q 2022). Revenue: CA$6.27m (up 39% from 3Q 2022). Net loss: CA$501.8k (loss narrowed 69% from 3Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
お知らせ • Aug 15Covalon Technologies Ltd. to Report Q3, 2023 Results on Aug 16, 2023Covalon Technologies Ltd. announced that they will report Q3, 2023 results Pre-Market on Aug 16, 2023
Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Amir Boloor was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Chairman of the Board Amir Boloor was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 27Second quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.095 loss in 2Q 2022)Second quarter 2023 results: CA$0.03 loss per share (improved from CA$0.095 loss in 2Q 2022). Revenue: CA$7.24m (up 120% from 2Q 2022). Net loss: CA$698.1k (loss narrowed 72% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
分析記事 • May 26We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 24Covalon Technologies Ltd. to Report Q2, 2023 Results on May 25, 2023Covalon Technologies Ltd. announced that they will report Q2, 2023 results Pre-Market on May 25, 2023
Reported Earnings • Feb 24First quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.043 loss in 1Q 2022)First quarter 2023 results: CA$0.02 loss per share (improved from CA$0.043 loss in 1Q 2022). Revenue: CA$6.19m (up 25% from 1Q 2022). Net loss: CA$380.8k (loss narrowed 66% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 18Covalon Technologies Ltd. to Report Q1, 2023 Results on Feb 23, 2023Covalon Technologies Ltd. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 23, 2023
Reported Earnings • Jan 26Full year 2022 earnings released: CA$0.36 loss per share (vs CA$0.016 profit in FY 2021)Full year 2022 results: CA$0.36 loss per share (down from CA$0.016 profit in FY 2021). Revenue: CA$18.1m (down 7.2% from FY 2021). Net loss: CA$9.25m (down CA$9.67m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 24Covalon Technologies Ltd. to Report Q4, 2022 Results on Jan 25, 2023Covalon Technologies Ltd. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 25, 2023
お知らせ • Dec 22Covalon Technologies Ltd., Annual General Meeting, Mar 08, 2023Covalon Technologies Ltd., Annual General Meeting, Mar 08, 2023.
お知らせ • Nov 02Covalon Technologies Ltd. Announces Its Newest Advanced Wound Care Product, ColActive Plus PowderCovalon Technologies Ltd. announced that its newest advanced wound care product, ColActive Plus Powder, was showcased in a case study presentation at the Symposium on Advanced Wound Care (SAWC), from October 13 to 16, 2022 in Las Vegas. The study, conducted by Dr. Alton Johnson Jr., DPM, FACPM, DABPM, CWSP, at University of Michigan School of Medicine, demonstrates the efficacy of ColActive Plus Powder in treating chronic non-healing wounds. Chronic, hard-to-heal wounds fail to advance through the phases of healing in an orderly and timely manner, often becoming stalled in the inflammatory phase. Imbalances in important cellular mediators for healing perpetuate the cycle of chronicity, which can lead to severe complications such as infection or amputation, which have grave consequences on overall quality of life. ColActive Plus Collagen Powder was uniquely designed to optimize the wound environment while supporting native collagen and connective tissue growth to help clinicians break the cycle of chronicity. Case Study Summary · An 83-year-old patient with peripheral arterial disease underwent metatarsal toe amputation which resulted in non-healing wounds. · The post-amputation surgical wounds failed to heal over several months with use of a competitive collagen/Oxidized Regenerated Cellulose product. · Treatment with weekly pulse lavage and ColActive Plus Powder resulted in the chronic post-amputation wounds being closed within 28 days, remaining healed to date. · Dr. Alton Johnson Jr. concluded that the use of the novel powder preparation of the ColActive formulation, in combination with pulse lavage, initiated and progressed the healing of the patient's chronic wounds rapidly, in addition to being simple to use as part of the existing treatment plan.Covalon's advanced wound care solutions include the following: ColActive® Plus Powder - Collagen wound filler that supports native collagen and connective tissue growth within the wound bed, while also stimulating cellular processes essential for wound healing. Allows for optimal moisture balance. Excellent solution for wounds of irregular shape or wounds in challenging locations ColActive® Plus Powder Ag - Collagen wound filler with antimicrobial ionic silver to prevent bacterial colonization within the product, thus minimizing the risk of infection.
お知らせ • Sep 27Covalon Technologies Ltd. to Showcase Infection Prevention Solutions at the Association for Vascular Access Annual Scientific MeetingCovalon Technologies Ltd. announced that it will be co-sponsoring the Association for Vascular Access (AVA) Annual Scientific Meeting and hosting an exhibit from September 30 to October 2, 2022 at the Minneapolis Convention Center, Minneapolis, Minnesota. Visit at booth 607 to learn about advanced infection prevention solutions that reduce the burden on patients, practitioners, and caregivers. Covalon's vascular access infection prevention solutions work to reduce central line-associated bloodstream infections (CLABSIs) while ensuring patient comfort and include: VALGuard - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. IV Clear- an antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin's barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation. VALGuard is the only FDA listed product specifically designed to help prevent vascular line to line contamination, with a safety release mechanism to allow instant access to the line in emergency situations. Vascular access line guards are being recognized as a must-have medical device by major hospitals as 71% of catheter-related infections have been linked to a catheter hub contamination. Patent-pending, VALGuard was developed specifically to help prevent these infections. IV Clear is the world's only clear dual-antimicrobial IV dressing with soft silicone adhesive technology that is designed to protect patients' skin – even after multiple dressing changes. Studies have shown the high efficacy of the product in preventing infections. What may not be as obvious, however, is that the product has been specifically designed with human experience in mind – patients, clinicians, and caregivers. Covalon's patented technology allows for significantly easier application, monitoring and removal, which is imperative for patients with vulnerable skin, such as pediatric ones.
お知らせ • Sep 14Covalon Technologies Ltd. to Introduce New Infection Prevention Products at the Annual Association of Pediatric Hematology/Oncology Nurses ConferenceCovalon Technologies Ltd. (the ‘Company’ or ‘Covalon’) to announce its participation in the 46th Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference & Exhibit at the Palm Beach County Convention Center in West Palm Beach, Florida on September 15 17, 2022. Visit Covalon at booth 307 to learn how their infection prevention and advanced wound care products are making a difference in the lives of their youngest patients. With more than 25 leading children's hospitals currently using or evaluating Covalon's VALGuard product, the world's only FDA-approved vascular access line guard, the need to find a solution to help protect line-to-line connections to reduce central line associated bloodstream infections (‘CLABSIs’) has never been greater. Bloodstream infections are up 65% in intensive care units, and there is an urgent need to adopt new compassionate care technologies in the fight to protect patients. The Conference provides premier educational content, networking, and social events for nurses specializing in pediatric hematology/oncology. Covalon will be hosting an exhibit throughout the conference dates. Visit them at booth 307 to learn how their infection prevention and advanced wound care products are making a difference in the lives of their youngest patients. Covalon's patented products include: VALGuard® - an FDA-approved, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal. SurgiClear® - a transparent, breathable, fluid impermeable barrier that isolates the wound site from external contamination while providing dual antimicrobial protection throughout the entire surface of the dressing. It uses a low but effective concentration of chlorhexidine and silver embedded into an atraumatic silicone adhesive that covers the entire transparent surface area to allow for easy and consistent monitoring of wound sites. IV Clear® - a vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin's barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
Reported Earnings • Aug 29Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.041 profit in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (down from CA$0.041 profit in 3Q 2021). Revenue: CA$4.53m (down 49% from 3Q 2021). Net loss: CA$1.61m (down 252% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 25Covalon Technologies Ltd. to Report Q3, 2022 Results on Aug 29, 2022Covalon Technologies Ltd. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 29, 2022
Reported Earnings • Jun 01Second quarter 2022 earnings released: CA$0.095 loss per share (vs CA$0.011 loss in 2Q 2021)Second quarter 2022 results: CA$0.095 loss per share (down from CA$0.011 loss in 2Q 2021). Revenue: CA$3.29m (down 24% from 2Q 2021). Net loss: CA$2.46m (loss widened CA$2.17m from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • May 27Covalon Technologies Ltd. to Report Q2, 2022 Results on May 30, 2022Covalon Technologies Ltd. announced that they will report Q2, 2022 results Pre-Market on May 30, 2022
お知らせ • May 20Covalon Technologies Ltd. Appoints Mark Doolittle as Senior Vice President, Commercial SalesCovalon Technologies Ltd. announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales. Mr. Doolittle brings over 20 years of medical and B2B sales and marketing experience to Covalon. He has substantial leadership experience managing high-performing teams and managing partnerships both domestically and internationally. Prior to joining Covalon, Mr. Doolittle spent the last 12 years at US-based Cantel Medical, the global leader in infection prevention in GI Endoscopy. In his most recent role, he served as the Vice President of US Commercial.
お知らせ • Apr 27Covalon Technologies Ltd. Appoints Ron Hebert as Senior Vice President of MarketingCovalon Technologies Ltd. announced that Ron Hebert has joined the Company as Senior Vice President of Marketing. Mr. Hebert brings nearly 30 years of healthcare sales, marketing, and hospital experience to Covalon. Prior to joining the Company, he served as Vice President of Marketing and Communications at VIVEX Biologics. He also served as Vice President and Head of Growth Marketing and Sales Operations at MEDNAX.
お知らせ • Feb 17Covalon Technologies Ltd. to Report Q1, 2022 Results on Mar 01, 2022Covalon Technologies Ltd. announced that they will report Q1, 2022 results Pre-Market on Mar 01, 2022
Reported Earnings • Dec 15Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CA$0.016 (up from CA$0.27 loss in FY 2020). Revenue: CA$19.6m (down 24% from FY 2020). Net income: CA$419.0k (up CA$7.37m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 3.5%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
Executive Departure • Oct 03Independent Director Myrna Francis has left the companyOn the 24th of September, Myrna Francis' tenure as Independent Director ended after 2.7 years in the role. We don't have any record of a personal shareholding under Myrna's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 5.92 years.
Executive Departure • Sep 29Independent Director Myrna Francis has left the companyOn the 24th of September, Myrna Francis' tenure as Independent Director ended after 2.7 years in the role. We don't have any record of a personal shareholding under Myrna's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 5.83 years.
Recent Insider Transactions • Sep 15Independent Chairman of the Board recently bought CA$103k worth of stockOn the 8th of September, Amir Boloor bought around 45k shares on-market at roughly CA$2.28 per share. This was the largest purchase by an insider in the last 3 months. Amir has been a buyer over the last 12 months, purchasing a net total of CA$184k worth in shares.
Reported Earnings • Sep 01Third quarter 2021 earnings released: EPS CA$0.041 (vs CA$0.012 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$8.82m (up 32% from 3Q 2020). Net income: CA$1.06m (up 237% from 3Q 2020). Profit margin: 12% (up from 4.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year whereas the company’s share price has fallen by 39% per year.
お知らせ • Jun 02Covalon Technologies Undertakes A Strategic Review ProcessAs previously announced, in response to expressions of interest made by medical industry and private equity organizations, Board of Directors of Covalon Technologies Ltd. (TSXV:COV) formed a Special Committee and hired advisors to assist in undertaking a Strategic Review process, to ensure that available strategic alternatives to enhance value for our shareholders are being evaluated. Amir Boloor, Chair of Covalon's Board of Directors and Chair of the Special Committee, said, “I am extremely pleased with the progress made by the Special Committee to date. Over the past several months, we have been carefully evaluating a number of expressions of interest and assessing the impact of these potential strategic alternatives on the overall value, future profitability and the growth prospects of Covalon. Each strategic alternative is being evaluated and assessed as to its impact following any strategic transactions involving one or more of our patented intellectual properties, technology platforms, commercialized medical product portfolio and global sales channels. This process has clearly validated that Covalon owns a number of valuable medical technologies that are of interest to the medical industry”.
Reported Earnings • Jun 02Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$6.74m (up 28% from 2Q 2020). Net income: CA$421.7k (up CA$4.33m from 2Q 2020). Profit margin: 6.3% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
分析記事 • Apr 29Is Covalon Technologies (CVE:COV) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 03First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.045 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: CA$5.99m (down 25% from 1Q 2020). Net loss: CA$372.3k (loss narrowed 68% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 82% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 27Covalon Technologies Ltd. to Report Q1, 2021 Results on Mar 01, 2021Covalon Technologies Ltd. announced that they will report Q1, 2021 results Pre-Market on Mar 01, 2021
Is New 90 Day High Low • Feb 20New 90-day high: CA$1.75The company is up 39% from its price of CA$1.26 on 20 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.
Reported Earnings • Jan 30Full year 2020 earnings released: CA$0.27 loss per share (vs CA$0.41 loss in FY 2019)The company reported a mediocre full year result with weaker revenues, although its control over expenses remained stable and losses reduced. Full year 2020 results: Revenue: CA$25.8m (down 24% from FY 2019). Net loss: CA$6.95m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 98% per year but the company’s share price has only fallen by 37% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Jan 27New 90-day high: CA$1.36The company is up 35% from its price of CA$1.01 on 28 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.
分析記事 • Dec 29Covalon Technologies (CVE:COV) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Nov 14Covalon Technologies Ltd. Appoints Amir Boloor as Chair of the Company's Board of DirectorsCovalon Technologies Ltd. announced the appointment of Amir Boloor, President of Caspian Equity Partners Inc., as Chair of the Company's Board of Directors. Mr. Boloor, an independent director of the Company, is also Chair of the Company's recently announced Special Committee, appointed to explore and evaluate a range of strategic alternatives available to the Company in order to enhance shareholder value.
お知らせ • Aug 22Covalon Technologies Ltd. to Report Q3, 2020 Results on Aug 24, 2020Covalon Technologies Ltd. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Aug 24, 2020
